White Blood Cell Transcriptome Correlates With Renal Function in Acute Heart Failure

Sebastian Szmit, MD, Michal Jank, DVM, Henryk Maciejewski, PhD, Pawel Balsam, MD, Alicja Majewska, PhD, Magdalena Loj, PhD, Marcin Grabowski, MD, Krzysztof J. Filipiak, MD, Tomasz Motyl, DVM, and Grzegorz Opolski, MD

SUMMARY

It is notoriously difficult to classify patients with acute heart failure (AHF) because of variations in clinical presentation, different etiologies, the impact of comorbidities, and variable prognoses. In this study, we used DNA whole-genome microarrays to classify 24 patients with AHF based on the transcriptome of their peripheral blood nuclear cells. The main purpose was to verify whether any transcriptomic sub-clusters had clinical correlations. We identified two distinct groups of transcriptomic profiles that correlated with normal (<1.125 mg/dL) and increased (1.783 mg/dL) mean blood creatinine concentrations. These two subgroups of patients (n = 12) differed in the expression of more than 6000 genes and 108 signaling pathways. The most significant regulated signaling pathway was the aldosterone-regulated sodium reabsorption pathway and the most significant regulated genes included the angiotensin-converting enzyme gene. This suggests that kidney impairment in patients with AHF is related to dysregulation of the renin-angiotensin-aldosterone system. The interesting findings of our study were the significant differences in expression of genes belonging to the aldosterone-regulated signaling pathway: Na+/K+ transporting ATPase and NEDD4L (neuronal precursor cell expressed developmentally down-regulated 4-like) between patients with and without renal dysfunction. Future studies of blood cell transcriptomic profiles in patients with AHF will provide further insights into the molecular pathogenesis of this cardiorenal disorder. (Int Heart J 2012; 53: 117-124)

Key words: Peripheral blood nuclear cells, Gene expression, Whole-genome DNA microarray analysis, RNA hybridization, Reverse transcription polymerase chain reaction, Serum creatinine, Aldosterone-regulated sodium reabsorption pathway

Because acute heart failure (AHF) occurs suddenly and frequently leads to death, it would be of considerable medical value to have predictive or prognostic biomarkers of myocardial infarction (MI) or AHF. In recent years, many attempts have been made to identify markers of heart failure. Neutrophil gelatinase-associated lipocalin/lipocalin-2 is one such biomarker. The concentration of this glycoprotein is elevated in the serum of patients with AHF after an MI, and this concentration is correlated with the degree of clinical deterioration.1 However, several other factors have also been described as biomarkers of MI, namely paraoxonase-1 and paraoxonase-2,2,3 5-lipoxygenase activating protein;3 soluble intercellular adhesion molecule 1, nuclear factor-κB inhibitor kinase, patatin-like phospholipase domain-containing protein 3, RELA, and SH2B adaptor protein 3;6 angiotensin-converting enzyme (ACE);6 vascular endothelial growth factor (VEGF);6,10 and cytotoxic T-lymphocyte antigen 4.11

Genetic factors have a significant role in the development of heart dysfunction. The sarcoglycan delta gene, for example, is implicated in heart failure in humans and hamsters, but not in dogs.11 Functional genomics and the use of DNA microarrays have allowed screening for a completely new class of markers, namely genomic markers. Genomic markers differ from genetic markers. Changes in genetic markers result from changes in gene structure (ie, gene mutations), whereas changes in genomic markers reflect altered expression of genes. A good example of such a marker is the chemokine CXCL16.12 Expression of the CXCL16 gene is increased in heart failure after MI, and plasma concentrations of the cytokine are increased in patients with chronic heart failure. In a previous study,13 we showed that the CXCL16 gene was up-regulated in peripheral blood nuclear cells of patients with end-stage heart failure. This suggests that peripheral blood nuclear cells could yield potential new genomic markers of heart disease. RNA in peripheral blood can only originate from white blood cells, which prompted us to hypothesize that such markers could reflect changes in the regulation of chemokines or other signaling molecules. Irrespective of the material investigated, technological advances now allow the simultaneous analysis of thousands of genes and the identification of many up- or down-regulated clustered genes. A recent review identified several potential genomic markers of heart failure, including APOB, APOE, ACE, PAI-1, MTHFR, CETP, eNOS, prothrombin, GWAS, CELSR2, PSRC1, SORT1, MRPS6, KCNE2, MIA3,
Characterization of the relationships between these genomic markers and the complete signaling pathways in which specific genes are involved might therefore provide insights into the molecular pathogenesis of heart disease.

The prognosis for patients with AHF is poor in both the short and the long term. Clinically, AHF is characterized by lung congestion, and sometimes pulmonary edema. Many patients have additional symptoms, such as reduced cardiac output and impaired peripheral perfusion. Severe AHF can lead to multiple organ failure and death, and therefore requires urgent medical intervention. AHF is usually a complication of an acute coronary syndrome. However, AHF sometimes develops in patients with chronic heart disease, despite appropriate treatment. This typically results from the progression of heart disease and concomitant noncardiovascular diseases. Unfavorable prognostic factors for AHF are similar to those in chronic heart failure. Clinically it is difficult to classify patients with AHF. For example, the clinical presentation is often different, and the etiology of the condition can vary. Comorbidities can also have an impact on the clinical picture, and the lack of a distinct prognosis can complicate the process of classification. Characterization of relevant molecular factors in patients with AHF would thus be useful.

In this study we attempted to classify patients with AHF based on the transcriptome of their peripheral blood nuclear cells and to verify whether any transcriptomic sub-clusters had clinical correlations. Using this novel approach, we looked for transcriptomic profiles of many differentially regulated genes, rather than for individual genes. Establishing a transcriptomic classification of patients with AHF would have prognostic value and could also provide information about disease pathogenesis.

**METHODS**

**Patients:** The study included 24 patients with a history of heart disease who were admitted to our Cardiology Department with a diagnosis of AHF. Patients with *de novo* AHF, MI with ST elevation as a cause of AHF, prehospital cardiac arrest, pulmonary embolism or stroke, cancer or severe lung disease, or a previous history of chronic kidney were excluded. All patients were diagnosed and treated according to the current clinical management guidelines.

Chest X-rays were performed on all patients to assess the degree of lung congestion. The following laboratory tests were performed: complete blood count, serum sodium, potassium, urea, creatinine, albumin, liver enzymes, prothrombin time/international normalized ratio (PT/INR) and troponin. Doppler echocardiography was performed to evaluate segmental and global systolic function of the left and right ventricles, diastolic ventricular function, and morphology and function of the heart valves.

The study was approved by the local Ethics Committee of the Medical University of Warsaw and all participants gave written informed consent.

**RNA isolation, validation, labeling, and hybridization:** Duplicate blood samples were obtained from the antecubital vein of each patient and collected in PAXGene tubes (Qiagen, USA). Total RNA from peripheral blood nuclear cells was isolated using a PAXgene Blood RNA kit (Qiagen, USA). Isolated RNA samples were dissolved in RNAase-free water, and the RNA quantity was measured spectrophotometrically using a NanoDrop (NanoDrop Technologies, USA). Samples with an adequate amount of RNA were treated with DNAase I to eliminate DNA contamination and then purified using an RNaseasy MiniElute Cleanup Kit (Qiagen, Germany). The analysis of final RNA quality and integrity was performed with a BioAnalyzer (Agilent, USA).

The analysis of gene-expression profile was performed using SurePrint G3 Human GE 8x60K (Agilent Technologies, USA). Each slide contained 8 microarrays representing about 60,000 predicted human mRNAs. Experiments were performed using a common reference design, where the common reference was a pool of equal amounts of RNA from all the patients. On each two-color microarray, we hybridized 100 ng of total RNA isolated from individual patients, and 100 ng of total RNA from the pool. Sample labeling, amplification, and microarray hybridization were performed with the appropriate kits supplied by the manufacturer of the microarrays (Agilent Technologies, USA), and according to the manufacturer’s protocols. Acquisition and analysis of hybridization intensities were performed using an Agilent DNA microarray scanner.

**Statistical analysis:** The raw probe data were loss normalized, and microarray probes not related to genes were discarded. Probes replicated in the array were then averaged. The log-ratio of the sample to the reference signal was calculated and the data were then median-centered. Clustering was performed for rows and columns of the gene expression matrix, where rows correspond to genes and columns correspond to samples. The measure of distance between (row or column) vectors was defined as 1 minus Spearman’s correlation coefficient between the vectors. A hierarchical clustering algorithm was used with Ward’s minimum variance linkage function. The groups identified in the unsupervised classification were correlated with clinical data from the patients. When correlations were found, the groups of patients were also compared using Student’s *t*-test for unequal variances and the nonparametric Wilcoxon rank test.

The groups of patients identified by correlation of unsupervised classification results and clinical data were compared for differentially expressed genes. The differential expression analysis was performed using linear methods for microarrays.

<table>
<thead>
<tr>
<th>Primer</th>
<th>L sequence</th>
<th>R sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATP1B3</td>
<td>CACCATGACGAAGAACGAGA</td>
<td>CTTGGGCTAGGAATCTGTCGA</td>
</tr>
<tr>
<td>NEDD4L</td>
<td>TTGAGGCATCAGGATGTCGA</td>
<td>GCAAGTGCATGATAGGTC</td>
</tr>
<tr>
<td>GAPDH</td>
<td>GAGTCAACGGATTTGTCGT</td>
<td>TTGATTCTGAGGAGATTTCG</td>
</tr>
</tbody>
</table>

**Table I.** Primers Used For Real-Time RT-PCR in This Study
Expressions of NEDD4L (the gene for E3 ubiquitin-protein ligase neural precursor cell expressed, developmentally down-regulated 4-like) and ATP genes were checked by real-time RT-PCR using ATP1B3, NEDD4L, and GAPDH primers (Table I). All analyses were performed on all individual samples of total RNA using a LightCycler FastStart DNA Master SYBR Green I kit (Roche Diagnostics GmBH, Germany) as follows: Mg$^{2+}$ was added to a final concentration of 3 mM; preincubation at 95°C for 10 minutes; amplification (40 cycles) including denaturation at 95°C for 10 seconds, annealing at 58°C (60°C for GAPDH) for 10 seconds, extension at 72°C for 10 seconds (12 seconds for GAPDH); melting curve including denaturation at 95°C for 0 seconds (slope = 0.1°C/s); cooling at 40°C for 30 seconds. Results were calculated using the 2-ΔΔC$^{T}$ method. The average expressions (with standard deviations) in both groups were compared using Student’s unpaired t-test in GraphPad Prism software (GraphPad, USA).

**RESULTS**

**Patient characteristics:** Patient characteristics are shown in Table II.

**Unsupervised classification:** The results of the unsupervised classification are shown in Figure 1. Cluster analysis revealed...
two groups of patients with distinct gene expression profiles: patient identity codes p17, p7, p13, p14, p1, p10, p11, p12, p2, p6, p21, p23 (group 1) and patient identity codes p18, p3, p5, p24, p19, p20, p9, p15, p4, p8, p16, p22 (group 2).

Correlation between unsupervised classification and clinical data: The groups identified by cluster analysis were correlated with clinical data for symptoms (pulmonary edema and low cardiac output), sex, age, history of heart disease, coexisting diseases, echocardiographic findings, etiology of AHF, the results of standard laboratory tests, and patient follow-up. The groups with different transcriptomic profiles also differed significantly in terms of blood creatinine concentration. The distribution of creatinine concentrations is shown in Figure 2. The groups were also compared using Student’s t-test for unequal variances and Wilcoxon’s nonparametric rank test, which gave $P = 0.029$ and $P = 0.035$, respectively. There were no other correlations between clinical and transcriptomic data. Moreover, there were no significant differences in clinical data between patients with normal (group 2) and increased (group 1) mean blood creatinine concentrations (Table II).

Differentially expressed genes identified by unsupervised classification: Analyses revealed about 6000 differentially expressed genes between the groups (false-discovery rate-adjusted $P$ value < 0.01) (data not shown). The data were reclustered in the space of the 2000 most differentially expressed genes, as shown in Figure 3. The results included 108 pathways which showed significant differential expression between groups (Holm adjusted $P < 0.05$ for the test of no association of expression in pathways with the group identity) (data not shown). The most significantly regulated signaling pathway was the aldosterone-regulated sodium reabsorption pathway (Holm-adjusted $P = 0.00000683$). This pathway consists of 39 different genes, 15 of which were differentially regulated (Table III).

Real-time PCR difference in NEDD4L and ATP1B3 genes in groups of patients identified by unsupervised classification: The expressions of NEDD4L and ATP1B3 genes measured using real-time PCR were in accordance with the expressions measured on microarrays (Table IV). The average expression of NEDD4L in group 2 was 1.6 times higher than that in group 1 (3.92 times higher on microarrays), whereas ATP1B3 expression in group 2 was 1.811 times lower than in group 1 (3.25 times lower on microarrays). For both genes the differences were statistically significant ($P < 0.05$).
Table III. Differentially Expressed Genes From the Aldosterone-Regulated Sodium Reabsorption Pathway in Patients With Normal Mean Blood Creatinine Concentration (1.175 mg/dL) Compared With Patients With Increased Mean Blood Creatinine Concentrations (1.783 mg/dL)

<table>
<thead>
<tr>
<th>No</th>
<th>Gene Symbol</th>
<th>Description</th>
<th>logFC</th>
<th>T</th>
<th>P</th>
<th>Adjusted P</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>MAPK3</td>
<td>Homo sapiens mitogen-activated protein kinase 3 (MAPK3), transcript variant 1, mRNA [NM_002746]</td>
<td>0.57</td>
<td>5.51</td>
<td>0.0000098200</td>
<td>0.0003230000</td>
</tr>
<tr>
<td>2</td>
<td>PIK3CD</td>
<td>Homo sapiens phosphoinositide-3-kinase, catalytic, delta polypeptide (PIK3CD), mRNA [NM_005026]</td>
<td>0.66</td>
<td>4.89</td>
<td>0.0000488000</td>
<td>0.0007190000</td>
</tr>
<tr>
<td>3</td>
<td>FXYD4</td>
<td>Homo sapiens FXYD domain containing ion transport regulator 4 (FXYD4), mRNA [NM_173160]</td>
<td>0.87</td>
<td>8.42</td>
<td>0.0000585000</td>
<td>0.0008010000</td>
</tr>
<tr>
<td>4</td>
<td>PRKCA</td>
<td>Homo sapiens protein kinase C, alpha (PRKCA), mRNA [NM_002737]</td>
<td>-0.81</td>
<td>-4.42</td>
<td>0.0001640000</td>
<td>0.0015900000</td>
</tr>
<tr>
<td>5</td>
<td>ATP1A3</td>
<td>Homo sapiens ATPase, Na+/K+ transporting, alpha 3 polypeptide (ATP1A3), mRNA [NM_152296]</td>
<td>0.58</td>
<td>4.23</td>
<td>0.0002720000</td>
<td>0.0022600000</td>
</tr>
<tr>
<td>6</td>
<td>PDGK1</td>
<td>Homo sapiens 3-phosphoinositide dependent protein kinase-1 (PDGK1), transcript variant 1, mRNA [NM_002613]</td>
<td>-0.49</td>
<td>-4.13</td>
<td>0.0003460000</td>
<td>0.0026600000</td>
</tr>
<tr>
<td>7</td>
<td>PIK3R1</td>
<td>Homo sapiens phosphoinositide-3-kinase, regulatory subunit 1 (alpha) (PIK3R1), transcript variant 1, mRNA [NM_002613]</td>
<td>-0.76</td>
<td>-4.1</td>
<td>0.0003820000</td>
<td>0.0028400000</td>
</tr>
<tr>
<td>8</td>
<td>NEDD4L</td>
<td>Homo sapiens neural precursor cell expressed, developmentally down-regulated 4-like (NEDD4L), transcript variant j, mRNA [NM_001449067]</td>
<td>0.97</td>
<td>9.29</td>
<td>0.0006020000</td>
<td>0.0039100000</td>
</tr>
<tr>
<td>9</td>
<td>NR3C2</td>
<td>Homo sapiens nuclear receptor subfamily 3, group C, member 2 (NR3C2), transcript variant 1, mRNA [NM_000901]</td>
<td>-1.69</td>
<td>-3.64</td>
<td>0.0012400000</td>
<td>0.0066200000</td>
</tr>
<tr>
<td>10</td>
<td>ATP1B2</td>
<td>Homo sapiens ATPase, Na+/K+ transporting, beta 2 polypeptide (ATP1B2), mRNA [NM_0001678]</td>
<td>0.79</td>
<td>3.6</td>
<td>0.0001340000</td>
<td>0.0070200000</td>
</tr>
<tr>
<td>11</td>
<td>KRAS</td>
<td>Homo sapiens v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), transcript variant a, mRNA [NM_03360]</td>
<td>-0.84</td>
<td>-3.44</td>
<td>0.0020100000</td>
<td>0.0039300000</td>
</tr>
<tr>
<td>12</td>
<td>ATP1B3</td>
<td>Homo sapiens ATPase, Na+/K+ transporting, beta 3 polypeptide (ATP1B3), mRNA [NM_0001679]</td>
<td>-0.59</td>
<td>-3.25</td>
<td>0.0003300000</td>
<td>0.0135000000</td>
</tr>
<tr>
<td>13</td>
<td>ATP1B1</td>
<td>Homo sapiens ATPase, Na+/K+ transporting, beta 1 polypeptide (ATP1B1), transcript variant 1, mRNA [NM_001677]</td>
<td>-0.79</td>
<td>-3.24</td>
<td>0.0003600000</td>
<td>0.0137000000</td>
</tr>
<tr>
<td>14</td>
<td>IGF1</td>
<td>Homo sapiens insulin-like growth factor 1 (somatomedin C) (IGF1), transcript variant 4, mRNA [NM_000618]</td>
<td>0.71</td>
<td>3.18</td>
<td>0.0003890000</td>
<td>0.0153000000</td>
</tr>
<tr>
<td>15</td>
<td>PIK3CD</td>
<td>Homo sapiens phosphoinositide-3-kinase, catalytic, delta polypeptide (PIK3CD), mRNA [NM_005026]</td>
<td>-0.32</td>
<td>-2.59</td>
<td>0.0156000000</td>
<td>0.0427000000</td>
</tr>
<tr>
<td>16</td>
<td>SGK1</td>
<td>Homo sapiens serum/glucocorticoid regulated kinase 1 (SGK1), transcript variant 1, mRNA [NM_0005627]</td>
<td>-0.89</td>
<td>-2.45</td>
<td>0.0215000000</td>
<td>0.0545000000</td>
</tr>
<tr>
<td>17</td>
<td>ATP1A1</td>
<td>Homo sapiens ATPase, Na+/K+ transporting, alpha 1 polypeptide (ATP1A1), transcript variant 1, mRNA [NM_000701]</td>
<td>-0.25</td>
<td>-1.2</td>
<td>0.0437000000</td>
<td>0.0933000000</td>
</tr>
<tr>
<td>18</td>
<td>PIK3R2</td>
<td>Homo sapiens phosphoinositide-3-kinase, regulatory subunit 2 (beta) (PIK3R2), mRNA [NM_0005207]</td>
<td>0.43</td>
<td>2.09</td>
<td>0.0467000000</td>
<td>0.0982000000</td>
</tr>
</tbody>
</table>

Gene descriptions include the USA National Centre for Biotechnology Information Reference Sequence accession number. LogFC is the logarithmically transformed fold change in gene expression. T is the fold change calculated by Student’s t test; the P value was calculated using the t test; and Adjusted P allows for a false discovery rate < 0.01.

Table IV. Real-Time RT-PCR Expression of NEDD4L and ATP1B3 Genes in the Two Groups of Patients Identified by Unsupervised Classification

<table>
<thead>
<tr>
<th>Gene</th>
<th>Group 1 (mean ± SEM)</th>
<th>Group 2 (mean ± SEM)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATP1B3</td>
<td>1.245 ± 0.2218</td>
<td>0.6844 ± 0.1505</td>
<td>0.0475</td>
</tr>
<tr>
<td>NEDD4L</td>
<td>0.4925 ± 0.05817</td>
<td>0.7936 ± 0.08905</td>
<td>0.0013</td>
</tr>
</tbody>
</table>

**Discussion**

Our results suggest that it is possible to classify cardiac patients based on the transcriptomic profile of their peripheral blood nuclear cells, and that this classification correlates with their renal function. While we acknowledge that patients with AHF and kidney dysfunction can easily be identified solely by measuring their blood creatinine concentration, we believe that our study is the first to show that an elevated blood creatinine concentration is correlated with the gene expression pattern in peripheral blood nuclear cells. The unsupervised classification of the patient transcriptomic profiles using two different methods gave similar results. The transcriptomic analyses of patients with AHF yielded two distinct profiles. Differentially expressed genes in these two subgroups revealed more than 6000 genes, with a false-discovery rate less than 0.01. These two subgroups of patients with different transcriptomic profiles differed significantly in mean blood creatinine concentration, which suggests one group with normal renal function and a second group with impaired renal function. Since all patients had AHF, we conclude that transcriptomic profiling of peripheral blood nuclear cells by DNA microarray allowed the identification of renal injury in these cardiac patients. There were no correlations with any other clinical parameters that we assessed, eg, the presence of pulmonary edema, troponin concentrations, or echocardiographic findings.

There are several diseases that coexist with heart failure, including renal failure, anemia, chronic obstructive pulmonary disease, diabetes, depression, and breathing disorders during sleep. Increasingly, a spectrum of cardiorenal syndromes,22-24

together with the inter-relatedness and bidirectional interaction of the renal and cardiovascular systems, has been recognized. A meta-analysis of heart-failure studies showed that every second patient with heart failure has concomitant renal dysfunction.\(^{25}\) In this patient group, the occurrence of renal dysfunction is associated with a 50% increased risk of death. An analysis of 5 clinical trials demonstrates that the risk of death is more than two-fold higher (HR 2.31, 95% CI 2.18-2.44, \(P < 0.001\)) in patients with moderate to severe renal failure. If kidney function is defined by serum creatinine concentration (as in this study), the risk of death increases significantly with every 1 mg/dL increase in creatinine concentration.\(^{26,28}\)

These results illustrate that there are molecular differences within AHF patients that determine renal function, irrespective of their history of heart disease, other coexisting diseases, the etiology of the AHF, and echocardiographic and standard laboratory test results. Surprisingly, symptoms of pulmonary edema and low cardiac output, troponin concentration, the incidence of anemia, and markers of inflammation or liver function did not correlate with the blood-cell transcriptomic profile.

Our findings suggest that a subgroup of patients with AHF and renal dysfunction represents a separate disease subtype, for which alternative therapeutic procedures may be appropriate. Renal dysfunction correlates with an abnormal response of the renin-angiotensin-aldosterone (RAA) system. Drugs that act on this system (eg, ACE inhibitors and aldosterone antagonists) reduce the risk of death in patients with heart failure. However, the evidence for this comes from studies mainly in patients with normal renal function. Data about whether these drugs improve the prognosis of patients with renal dysfunction is less reliable. Our findings indicate that the results for RAA-targeted therapy should not be extrapolated to patients with elevated serum creatinine, because there are significant molecular differences in this group. In addition, drugs that interfere with the RAA system worsen renal function, leading to further increases in creatinine concentrations. Although Ezekowitz, et al.\(^{29}\) showed that patients with renal dysfunction may benefit from ACE-inhibitor therapy, patients in this group rarely receive optimal therapy consistent with current management guidelines. Interestingly, ACE is also considered to be a potential genetic marker of both MI\(^{30}\) and kidney failure.\(^{31,32}\) In our study, the expression of the ACE gene was differentially regulated in patients with and without kidney dysfunction, which suggests that in some patients, but not others, the development of AHF is associated with changes in ACE gene expression. Some patients may have low expression of ACE even before the development of AHF, which could explain why treatment with ACE-inhibitors is unsuccessful in these patients.

The differentially expressed genes identified in our study represented 108 different signaling pathways. Of these, the most significant differentially regulated pathway was the aldosterone-regulated sodium reabsorption pathway (Holm-adjusted \(P < 0.00000683\)). This pathway consists of 39 different genes of which we identified 15 regulated genes (adjusted \(P < 0.05\)). Notably, net changes in the expression of individual genes were not remarkable, but over the pathway as a whole the altered level of expression was highly significant. This suggests that significant regulation of a whole signaling pathway can occur in the absence of major changes in the expression of individual genes. Consistent with this, we assume that the changed aldosterone-regulated sodium reabsorption pathway is a consequence of altered expression of the ACE gene because regulation of ACE expression would lead to changes in aldosterone concentrations.

In patients with heart failure, aldosterone is secreted not only by the adrenal glands, but also by cardiomyocytes and vascular myocytes.\(^{33,34}\) Aldosterone stimulates collagen production, leading to adverse structural remodeling of the heart and blood vessels,\(^{34,41}\) and activates the sympathetic nervous system.\(^{35}\) Clinically, the effects of aldosterone overactivity are fluid overload, cardiac dysfunction and ventricular arrhythmias,\(^{36}\) resulting in increased mortality.\(^{37}\) Randomized clinical trials have demonstrated that the use of the aldosterone antagonists spironolactone and eplerenone prolongs the lives of patients with heart failure.\(^{38-40}\) Our study indicated that the aldosterone-dependent signaling pathway is most significantly regulated in patients with AHF and increased blood creatinine levels, which further suggests that drugs that act on this pathway could be of clinical importance in patients with heart failure.

The changes in the expression of genes belonging to the aldosterone-regulated signaling pathway were confirmed by real-time PCR, which revealed increased expression of Na\(^+\)/K\(^+\) transporting ATPase (represented within the pathway by 7 genes coding different ATPase subunits) and NEDD4L. We know that reduced Na\(^+\)/K\(^+\) ATPase activity has been demonstrated in patients with heart failure and dilated cardiomyopathy.\(^{41,42}\) This reduced activity correlates with a decrease in LVEF\(^{43}\) and the risk of cardiac arrhythmias.\(^{44}\) Significant changes in the activity of the sodium-potassium pump have also been observed in patients with myocardial ischaemia.\(^{45,46}\) NEDD4L is a regulator of the amiloride-sensitive epithelial sodium channel,\(^{47}\) and plays an important role in cardiovascular disease, especially hypertension. Variants of the NEDD4L gene may also contribute to individual variations in blood pressure\(^{48}\) and to the outcome of treatment. For example, Svensson-Färbom, et al.\(^{49}\) showed that polymorphism in the NEDD4L gene (rs4149601) influences the efficacy of \(\beta\)-blocker- and/or diuretic-based antihypertensive treatment but not diltiazem-based antihypertensive treatment. If the changes in the regulation of these two signaling components would be correlated with treatment efficacy in patients with heart failure (which requires further studies), they might become a genetic and genomic marker of kidney failure in AHF patients.

The search for potential genomic biomarkers of heart or kidney failure within peripheral blood nuclear cells seems reasonable given the increasing use of blood cells in cardiovascular research. According to Horwitz, et al.\(^{50}\) expression profiles of blood cells may be a more sensitive screening test for cardiac allograft rejection than endomyocardial biopsy. Peripheral blood gene expression is also correlated with the extent of coronary heart disease\(^{51}\) and chronic heart failure,\(^{52}\) and could be used to differentiate patients with ischemic end-stage heart failure from patients with asymptomatic heart dysfunction.\(^{53}\) Recently, Devaux, et al.\(^{54}\) identified a set of 3 potential biomarkers (VEGFB, THBS1 and PGF) of left ventricular dysfunction in blood cells from patients after MI. One of these genes, THBS1, was also regulated in our study and was found to differ significantly in patients with kidney dysfunction. Peripheral blood genomic biomarkers also have potential in discriminating acute rejection from nonrejection in cardiac transplant re-
cipients.\(^{54}\) Investigation of the blood cell transcriptomic profiles in patients with cardiovascular disorder thus appears to be a promising field of research.

In summary, we have shown for the first time that the transcriptomic profile of peripheral blood nuclear cells in patients with AHF is correlated with the concentration of blood creatinine. Among patients with AHF, we were able to identify distinct and separate transcriptomic profiles for patients with kidney failure (mean blood creatinine concentration = 1.783 mg/dL) and those with healthy kidneys (mean creatinine concentration = 1.175 mg/dL). The regulated signaling pathway that differed most significantly between these two patient groups was the aldosterone-regulated sodium reabsorption pathway. This differential expression, together with the regulation of ACE gene expression, points to a critical role for kidney function (and the RAA system) in patients with heart failure. Larger, long-term studies are needed to assess whether the potential associations between these correlate with long-term survival and treatment effectiveness in these patients. Such studies may also help identify the molecular processes involved in AHF in humans.

**References**

47. Dahlberg J, Nilsson LO, von Wwonn F, Melander O. Polymorphism in NEDD4L is associated with increased salt sensitivity, reduced levels of P-rnen and increased levels of Nt-proANP. PLoS One 2007; 2: e432.